Overview

KSH01-TCRT Solid Tumors

Status:
Recruiting

Trial end date:
2027-07-31

Target enrollment:

Participant gender:

Summary

1) Safety and efficacy of TCR-T cells in subjects with refractory/relapsed solid tumors. 2) The activation and proliferation of TCR-T cells in the subject, and the survival time.

Phase:

Early Phase 1

Details

Lead Sponsor:

TCRx Therapeutics Co.Ltd